Off-label stent use was high at 78% for sirolimus-eluting stents, 76% for everolimus-eluting stents and 75% for bare-metal stents.
One-third of patients had unstable angina, and two-thirds presented with acute coronary syndromes, and half of these had MI with ST-segment elevation.
BASKET-PROVE was sponsored by the Basel Cardiovascular Research Foundation and the Swiss National Foundation for Research. Dr. Kaiser and his coauthors report serving on the speakers bureau or as a consultant/adviser for several companies, including Biotronik, Abbott Vascular, Eli Lilly, Daiichi-Sankyo, and Astra Zeneca.